AMIN MAYSAA NAJAH1*, ABBOODABDULADHEEMYASEEN.2, AL-MASHTA SARMAD ABDULRASOOL
Myelin oligodendrocyte glycoprotein (MOG) is considered as a biokmaker in multiple sclerosis patients, MOG is unique to the brain, it is located on the outer lamellae of oligodendroglial membranes and myelin and it is highly immunogenic.Objective:In the present study an evaluation of serum anti-MOG antibody in relapsing remitting multiple sclerosis (RRMS)patientswas carried out. Method:Serum levels of anti-MOG were measured by ELISA method after venous blood was collected from forty MS patients and forty healthy subjects as control group. Absorbance was read at a wave length of 450nm using ELISA reader. Anti-MOG antibody level was then calculated by plotting the optical density (O.D.) of each sample against the concentration in the standard curve. Results:A significant difference between serum Anti-MOG concentration in patients 554.85 ± 39.73pg/ml and the control group with 315.20 ± 28.49pg/ml, (p=0. 0211) was found. Also Anti-MOG has a negative correlation between age and concentration (r= -0.12) and significant positive correlation between expanded disability status scale (EDSS) and concentration (r= 0.28). Conclusion:Data for serum level of Anti-MOG Ab are present in this study. They are a basis for the role of Anti-MOG inmultiple sclerosis patients. The present findings showed an increased levels of anti-MOG antibody in patient group which may suggest the demyelinating role of anti-MOG antibody and the importance of humoral immunity in relapsing remitting multiple sclerosis patients. Therefore the data found in this work might be used for further study on the importance of humoral immunity in autoimmune disease like MS.